Clinical trials: Sugammadex
Anesthesia, General
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
The purpose of the trial is to demonstrate a faster recovery from neuromuscular block (NMB) induced with rocuronium or vecuronium after reversal by 4.0 mg/kg of Org 25969 compared with reversal by 70 μg/kg of neostigmine in…
- Trial name
- NCT00473694
- Testing
- sugammadex, neostigmine, vecuronium
- Volunteers
- 182 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuromuscular Blockade
Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
The primary objective of this study is to explore the dose-response relation of MK-8616 (Org 25969) given as a reversal agent of Zemuron® at 1 to 2 post tetanic counts (PTCs); both Zemuron® and MK-8616 are administered by…
- Trial name
- NCT03519867
- Testing
- MK-8616, Zemuron®
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)
The purpose of this study was to demonstrate in adult patients a faster recovery from a neuromuscular block with 2.0 mg/kg Org 25969 (sugammadex) after rocuronium as compared to 50 ug/kg neostigmine after cisatracurium when…
- Trial name
- NCT00451100
- Testing
- Sugammadex, neostigmine
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Anesthesia, General
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
The primary purpose of the study is to determine the time-course of recovery to a T4/T1 ratio of 0.9 within 4 minutes after 4.0 mg.kg^-1 Sugammadex is administered at least 15 minutes after the last administration of rocuronium…
- Trial name
- NCT00298831
- Testing
- Sugammadex, Rocuronium
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC